Peak Bio, Inc., based in Pleasanton, CA, is a biopharmaceutical company focused on developing innovative therapies for inflammatory rare and specialty diseases, as well as cancer. With a management team boasting over 50 years of industry experience, the company is dedicated to addressing significant unmet medical needs through its research and development in antibody-drug conjugates and small molecule therapeutics.
One of their notable investigational therapies is PHP-303, a small molecule inhibitor of Neutrophil Elastase aimed at treating a rare genetic condition known as Alpha-1 Antitrypsin Deficiency (AATD). Additionally, Peak Bio is exploring novel toxins and antibody-drug conjugates (ADCs) that combine the precision of monoclonal antibodies with the potent effects of targeted small molecule therapies for oncology applications.
Generated from the website